Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma
Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine
Charbone Hydrogene Annonce un Financement de Reglements de Dettes par Emission d'Unites pour un Montant Total de 1,3M$
